RSCI (Redwood Scientific Technologies) LT-Debt-to-Total-Asset: 0.00 (As of Dec. 2023)


What is Redwood Scientific Technologies LT-Debt-to-Total-Asset?

Redwood Scientific Technologies RSCI LT-Debt-to-Total-Asset is 0.00 as of Dec. 2023.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Redwood Scientific Technologies's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.00.

Redwood Scientific Technologies's long-term debt to total assets ratio stayed the same from Dec. 2021 (0.00) to Dec. 2023 (0.00).

Redwood Scientific Technologies  (OTCPK:RSCI) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Redwood Scientific Technologies LT-Debt-to-Total-Asset Related Terms

Redwood Scientific Technologies LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Redwood Scientific Technologies's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Redwood Scientific Technologies LT-Debt-to-Total-Asset Chart

Redwood Scientific Technologies Annual Data
Trend Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
0.00 0.00 0.00 0.00

Redwood Scientific Technologies Semi-Annual Data
Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset 0.00 0.00 0.00 0.00

Redwood Scientific Technologies LT-Debt-to-Total-Asset Calculation

Redwood Scientific Technologies's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0/0.296
=

Redwood Scientific Technologies's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )/Total Assets (Q: Dec. 2023 )
=0/0.296
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.00 mean?
Redwood Scientific Technologies (RSCI) has a LT-Debt-to-Total-Asset of 0.00 as of Dec. 2023. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Redwood Scientific Technologies and its competitors.
Is Redwood Scientific Technologies' LT-Debt-to-Total-Asset too high?
Redwood Scientific Technologies' current LT-Debt-to-Total-Asset is 0.00.
How does Redwood Scientific Technologies' LT-Debt-to-Total-Asset compare to RAPH and FLGC?
Redwood Scientific Technologies' LT-Debt-to-Total-Asset of 0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Drug Manufacturers company?
A good LT-Debt-to-Total-Asset depends on the Drug Manufacturers industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Redwood Scientific Technologies and its competitors. Redwood Scientific Technologies's current LT-Debt-to-Total-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Redwood Scientific Technologies stock overvalued right now?
Redwood Scientific Technologies (RSCI) has a current LT-Debt-to-Total-Asset of 0.00. The current LT-Debt-to-Total-Asset is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Redwood Scientific Technologies (RSCI), the current LT-Debt-to-Total-Asset is 0.00 as of Dec. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Redwood Scientific Technologies Business Description

Address 418 Broadway, STE 4872, Albany, NY, USA, 12207
Redwood Scientific Technologies Inc is a pharmaceutical delivery company that develops, operates, and markets over-the-counter products in a sublingual oral thin film strip. RSCI has begun clinical trials on two new products to market for stopping the addiction to nicotine.